8-K: Sanuwave Health Reports Preliminary Q2 2026 Revenue Above Guidance

Sanuwave Health announced preliminary Q2 2026 revenues are expected to be between $9.6 million and $9.8 million, exceeding its revised guidance.

Summary

• Sanuwave Health announced preliminary, unaudited revenues for the second quarter ended June 30, 2026, are projected to be between $9.6 million and $9.8 million.
• This revenue range is above the company's revised guidance of $8.5 million to $9.5 million.
• However, preliminary Q2 revenues represent a decrease of approximately 35% compared to $10.1 million in the second quarter of 2025.
• CEO Morgan Frank cited capital sales headwinds due to customer financial stress and the sale of used Ultramist systems as reasons for the year-over-year decrease.
• The company is implementing a program to help qualify, train, and support new users of used systems, offering trade-in terms for certified pre-owned systems with a manufacturer's warranty.
• Sales of consumable applicators reached all-time records for both unit sales and revenues in Q2 2026, indicating growing confidence in Ultramist and a promising trend for future recurring revenue.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive filing. While revenue exceeded guidance, the year-over-year decline is a concern. However, record consumable sales indicate strong product adoption and future revenue potential.

Positives

• Preliminary Q2 2026 revenue of $9.6 million to $9.8 million exceeded the high end of the revised guidance range ($8.5 to $9.5 million).
• Sales of consumable applicators set all-time records for both unit sales and revenues in Q2 2026.
• The company's trade-in program for used Ultramist systems is showing success in converting users to certified pre-owned systems with warranties.

Negatives

• Preliminary Q2 2026 revenues are down approximately 35% compared to $10.1 million in Q2 2025.
• Capital sales faced headwinds due to financial stress within the customer base.
• The sale of used Ultramist systems is impacting new system sales.

Risks

• Reductions, clawbacks, or recoupments of CMS reimbursement for advanced wound care products could affect customer behavior and capital budgets.
• Financial distress, closure, or liquidation of wound care practices may reduce demand for the Company's systems.
• The emergence and growth of a secondary market for used Ultramist systems could cannibalize sales of new systems.
• The company faces risks related to qualifying, training, and supporting new users of systems acquired through the secondary market, including regulatory, quality, and product-liability considerations.
• The ability to sustain applicator and consumable volumes and convert system placements into recurring consumable revenue is a risk.
• Potential differences between updated guidance and final reported results after quarter-end close.
• Risks associated with regulatory oversight.
• The company's ability to manage its capital resources and competition.

Future Outlook

The company expects to provide more details on Q2 earnings in August. The success of consumable applicator sales is seen as a promising trend for future recurring revenue. The company is working to help new users of used systems and offer trade-in terms for certified pre-owned systems.

Management Comments

• "Q2 came in a bit above the top of the range that we laid out back in June," said CEO Morgan Frank.
• "The business played out largely as we had forecast with capital sales facing headwinds from stress in our customer base and from the sale of used Ultramist systems in our market."
• "Sanuwave will always seek to do whats best for the patients, so weve been working to help qualify, train, and support such new users and offering attractive trade-in terms such that units purchased used can be traded in for certified pre-owned systems that would carry a manufacturers warranty."
• "This program has been showing success so far."
• "The good news in the quarter is that sales of consumable applicators set all time records for both unit sales and revenues, both by significant margins."
• "We see this as an indication of both increasing interest and confidence in Ultramist as a wound care modality and, obviously, as consumables are the core of any razor-razorblade business, as a promising trend for the future."
• "We look forward to speaking with you more about this when the Company reports Q2 earnings in August."

Industry Context

StockSavvy.ai notes that Sanuwave Health's preliminary Q2 results highlight a common challenge in medical device sales: the impact of customer financial health and the emergence of secondary markets for equipment. While capital equipment sales face headwinds, the record sales of consumables suggest a strong underlying demand for the technology and a potential for recurring revenue, a key indicator for sustainable growth in the advanced wound care sector.

Stakeholder Impact

• Shareholders: May see a positive reaction to exceeding guidance, but the year-over-year revenue decline could temper enthusiasm. The strong consumable sales offer a positive outlook for future profitability.
• Customers: Experiencing financial stress, potentially impacting capital equipment purchases. The trade-in program offers an avenue for acquiring certified pre-owned systems.
• Employees: The company's performance and outlook will influence job security and morale. Strong consumable sales could indicate continued operational needs.
• Suppliers: Continued demand for consumables, indicated by record sales, suggests ongoing business for suppliers of these components.

Next Steps

• Complete quarter-end financial close and review procedures.
• Report Q2 earnings in August 2026.
• Continue to qualify, train, and support new users of used Ultramist systems.
• Continue to offer attractive trade-in terms for certified pre-owned systems.

Key Dates

Recommendation

The company exceeded its revised revenue guidance, which is a positive sign. However, the significant year-over-year revenue decline and ongoing headwinds in capital sales warrant caution. The strong performance in consumable sales is a key positive, suggesting underlying demand and a path to recurring revenue. A 'hold' recommendation reflects the balance between exceeding short-term expectations and the persistent challenges in the business environment.

Keywords

Sanuwave Health, Ultramist, Directed Energy Systems, Advanced Wound Care, Revenue, Q2 2026, Consumables, Financial Results